The Pain Management Devices And Therapies Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pain Management Devices And Therapies Market:
https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report
According to The Business Research Company’s Pain Management Devices And Therapies Global Market Report 2024, The pain management devices and therapies market size has grown rapidly in recent years. It will grow from $4.38 billion in 2023 to $4.83 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of chronic pain, growing demand for minimally invasive pain management procedures, increasing demand for personalized pain management, growing geriatric population, increasing awareness of pain management options.
The pain management devices and therapies market size is expected to see rapidly grown in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to non-opioid alternatives, remote and digital health, rising opioid epidemic, growing popularity of integrative pain management, value-based care. Major trends in the forecast period include advances in pain management technology, neuromodulation devices, digital therapeutics, wearable pain management devices, regenerative therapies.
An increase in demand for pain management devices due rise in chronic diseases is driving the growth of the pain management devices and therapies market. Chronic diseases such as cancer, heart stroke often lead to unbearable pain in patients and thus creating a demand for pain management drugs and therapies. Chronic diseases persist over a long period and deteriorate the health of the patient. As reported in an article by the Brazilian Journal of Nephrology, around 60% of patients with chronic kidney disease reported pain of any kind of intensity, which required pain management drugs. Similarly, according to a report in the ‘US National Library of Medicine, approximately 45% or 133 million of all Americans suffered from at least one chronic disease. It is also stated that more than two-thirds of all deaths are due to one of the chronic illnesses, which included coronary heart sickness, cancer, stroke, persistent obstructive pulmonary disease, and diabetes. This rise in chronic diseases is increasing the demand for pain management devices and therapies and driving the pain management devices and therapies market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=2490&type=smp
The pain management devices and therapies market covered in this report is segmented –
1) By Type: Electrical Stimulators, Ablation Devices, Neurostimulators, Analgesic Pumps
2) By Neurostimulation Devices: Spinal Cord Stimulation (SCS) Devices, Deep Brain Stimulation Devices, Vagus Nerve Stimulation Devices, Sacral Nerve Stimulation Devices
3) By Electrical Stimulation Devices: Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Neuromuscular Electrical Stimulation (NMES/EMS) Devices, Combination Devices, Electrotherapy Devices, TNS
4) By Ablation Devices: Radiofrequency Ablation Devices, Cryoablation Devices
5) By Analgesic Infusion Pumps: Intrathecal Infusion Pumps, External Infusion Pumps
6) By Application: Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, Trauma
Companies in the parathyroid hormone market are focusing on developing biosimilars of parathyroid-based drugs. A biosimilar is a biological product that is developed to be similar to an already FDA-approved biologic, known as the reference product. Biosimilars potentially offer consumers the opportunity to reduce their healthcare costs without compromising on treatment standards, which is why parathyroid hormone manufacturing companies are investing in them. For instance, in January 2021, Theramex a UK-based pharmaceutical company launched Livogiva. Teriparatide, the only bone anabolic medication for osteoporosis, is now available in a novel form called Livogiva, a pre-filled pen that makes it simple for patients who are at high risk of osteoporosis to take. Livogiva is recommended for postmenopausal women with osteoporosis who are at higher risk of fracture .
The pain management devices and therapies market report table of contents includes:
1. Executive Summary
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The starter credit cards global market report 2024 from The Business Research Company provides comprehensive…
The school bus global market report 2024 from The Business Research Company provides comprehensive market…
The polyethylene terephthalate (pet) cups global market report 2024 from The Business Research Company provides…
The organic pet food global market report 2024 from The Business Research Company provides comprehensive…
The octadecanedioic acid global market report 2024 from The Business Research Company provides comprehensive market…
The mobile enterprise application global market report 2024 from The Business Research Company provides comprehensive…